Outcomes for Oligometastatic and Oligorecurrent Cervical Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicentre, retrospective registry collecting real‑world data on patients with induced oligo‑metastatic or oligo‑recurrent cervical cancer identified using an adapted ESTRO‑ASTRO definition. The project will describe treatment patterns, including high‑dose radiotherapy, stereotactic ablative radiotherapy, re‑irradiation, surgery or ablation, given alone or with systemic chemotherapy, immunotherapy, or targeted agents. Primary outcome is overall survival, with secondary endpoints including in‑field and overall progression‑free survival, treatment‑related toxicity, and development of prognostic risk groups. The registry will also support development of a nomogram and a framework to inform future prospective trials.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Cervical cancer with (induced) oligo-metastatic and/or oligo-recurrent cervix cancer whether treated or not treated with radiation. These patients may have received previous treatment within or outside approved clinical trials/studies.
2. Patients with poly-metastatic disease with good response to systemic chemotherapy and treated with radiation to recurrence or metastatic site.
3. Patients treated with radical doses at the time of first diagnosis of oligo-metastasis/oligo-recurrence and present with further oligo-progression.
4. Patients with oligo-metastasis or oligo-recurrence treated with other locally directed therapies (like surgery, ablation, etc.) are also permitted.

Exclusion Criteria:

1. Gynaecological cancer other than cervical cancer.
2. Persistent Poly-metastatic disease post systemic treatment
3. Receiving investigational new drugs at the time of relapse as part of other ongoing trials.
4. No clinical follow up after treatment

Where it's running

• Tata Memorial Hospital
  Mumbai, Maharashtra, India Recruiting

Study contacts

• Principal investigator: Dr. Supriya Chopra, MD — ACTREC, Tata Memorial Centre, Navi Mumbai India
• Study coordinator: Dr. Supriya Chopra, MD
• Email: supriyasastri@gmail.com
• Phone: 9930958309

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Targeted Induction Therapy for Stage III Unresectable EGFR Mutant NSCLC

  This trial tests a targeted induction approach using fumetinib with platinum-based chemotherapy and concurrent radiochemotherapy in adults with unresectable stage III EGFR-mutant NSCLC to see if this combo can improve outcomes before possible surgery.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07742332

• Tracking fluid buildup (edema) in people with cancer

  This will try segmental bioelectrical impedance analysis to see if it can monitor local fluid buildup in cancer patients who have arm or leg swelling after radiotherapy or chemotherapy.

  Recruiting University of Copenhagen · Aalborg, The North Denmark Region · NCT07443618

• Intestinal Low-Dose Radiotherapy plus Immunochemotherapy to Convert Borderline Resectable or Unresectable Esophageal Squamous Cell Carcinoma

  This study tests whether adding a very low dose intestinal radiotherapy with immunochemotherapy can make advanced esophageal squamous cell carcinoma operable for patients who can’t be surgically removed today.

  Recruiting Phase 2 Shantou University Medical College · Shantou, Guangdong · NCT07339488

• β-hydroxybutyrate with short-course radiotherapy, immunotherapy and CAPEOX before surgery for locally advanced rectal cancer

  This phase II trial will test whether adding β-hydroxybutyrate supplements to short-course radiotherapy followed by immunotherapy plus CAPEOX chemotherapy improves outcomes for people with locally advanced rectal cancer before surgery.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07239466

• Adebelizumab with chemotherapy given with radiotherapy at the same time versus after radiotherapy for extensive-stage small cell lung cancer

  This study tests whether adding adebelizumab to chemo and radiotherapy works better when given at the same time as radiotherapy compared to after radiotherapy in adults with extensive-stage SCLC.

  Recruiting Phase 2 Peking University Cancer Hospital & Institute · Beijing, Beijing Municipality · NCT06768307

• Comparing total neoadjuvant therapy with surgery for rectal cancer treatment

  This study is testing if rectal cancer patients who respond well to a new treatment can skip surgery and just be monitored to see how they do compared to those who have surgery right away.

  Recruiting Phase 2/3 National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos · Vilnius · NCT06758830

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.